Hepatotoxicity of contemporary antiretroviral drugs.

IF 4.5 3区医学 Q2 IMMUNOLOGY

Current Opinion in HIV and AIDS Pub Date : 2021-11-01 DOI:10.1097/COH.0000000000000706

Christina G Rivera, Ashley O Otto, John D Zeuli, Zelalem Temesgen

{"title":"Hepatotoxicity of contemporary antiretroviral drugs.","authors":"Christina G Rivera, Ashley O Otto, John D Zeuli, Zelalem Temesgen","doi":"10.1097/COH.0000000000000706","DOIUrl":null,"url":null,"abstract":"Purpose of review: To date, more than 30 antiretroviral drugs have been approved by the Food and Drug Administration for the treatment of HIV infection. As new drugs with better efficacy and safety profile become available for clinical practice, older drugs are either withdrawn from the market or become no longer actively prescribed. We review hepatotoxicity associated with contemporary antiretroviral drugs, with emphasis on data from the past 3 years.Recent findings: Although less robust data exists for side effects of contemporary antiretroviral medications recently approved for the management of HIV (i.e., doravirine, ibalizumab, fostemsavir, cabotegravir), the risks of substantial hepatotoxicity appears to be minimal with these agents.Summary: Although newer antiretroviral drugs are better tolerated than their earlier counterparts, they are not completely devoid of adverse drug reactions, including hepatotoxicity. Monitoring patients on antiretroviral therapy for treatment-emergent liver injury should continue to be part of routine clinical care.","PeriodicalId":10949,"journal":{"name":"Current Opinion in HIV and AIDS","volume":"16 6","pages":"279-285"},"PeriodicalIF":4.5000,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in HIV and AIDS","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/COH.0000000000000706","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Purpose of review: To date, more than 30 antiretroviral drugs have been approved by the Food and Drug Administration for the treatment of HIV infection. As new drugs with better efficacy and safety profile become available for clinical practice, older drugs are either withdrawn from the market or become no longer actively prescribed. We review hepatotoxicity associated with contemporary antiretroviral drugs, with emphasis on data from the past 3 years.

Recent findings: Although less robust data exists for side effects of contemporary antiretroviral medications recently approved for the management of HIV (i.e., doravirine, ibalizumab, fostemsavir, cabotegravir), the risks of substantial hepatotoxicity appears to be minimal with these agents.

Summary: Although newer antiretroviral drugs are better tolerated than their earlier counterparts, they are not completely devoid of adverse drug reactions, including hepatotoxicity. Monitoring patients on antiretroviral therapy for treatment-emergent liver injury should continue to be part of routine clinical care.

查看原文本刊更多论文

当代抗逆转录病毒药物的肝毒性。

审查目的:迄今为止，食品和药物管理局已经批准了30多种抗逆转录病毒药物用于治疗艾滋病毒感染。随着具有更好疗效和安全性的新药可用于临床实践，老药要么退出市场，要么不再被积极处方。我们回顾了与当代抗逆转录病毒药物相关的肝毒性，重点是过去3年的数据。最近的发现:尽管最近批准用于治疗HIV的当代抗逆转录病毒药物(即doravirine, ibalizumab, fostemsaver, cabotegravir)的副作用数据较少，但这些药物的严重肝毒性风险似乎很小。摘要:尽管较新的抗逆转录病毒药物比早期的药物耐受性更好，但它们并非完全没有药物不良反应，包括肝毒性。对接受抗逆转录病毒治疗的患者进行紧急肝损伤监测应继续作为常规临床护理的一部分。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in HIV and AIDS IMMUNOLOGY-INFECTIOUS DISEASES

CiteScore

7.40

自引率

7.30%

发文量

115

审稿时长

6-12 weeks

期刊介绍： Published bimonthly and offering a unique and wide ranging perspective on the key developments in the field, each issue of Current Opinion in HIV and AIDS features hand-picked review articles from our team of expert editors. With six disciplines published across the year – including HIV and ageing, a HIV vaccine, and epidemiology – every issue also contains annotated reference detailing the merits of the most important papers.